ClinicalTrials.gg
CompletedNCT01277302Updated Apr 23, 2014Results posted

A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion

A Phase 4 interventional study of Ranibizumab in Macular Edema, sponsored by Genentech, Inc.. Completed at 42 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-04-23.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
202
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 91 studies testing ranibizumab in Macular Edema — none open to participants now, none under way, none of them phase 3. Ranibizumab · Macular Edema.

Enrollment
21st of 91
202 · median 50
Started
2011
with 10 others
Phase 4
26 of 91
none open now
Registered
27th of 91
by date
Lead sponsor
7 of 91
Genentech, Inc.

Among the 91 studies testing ranibizumab in Macular Edema, this one is the 21st largest by enrollment, is one of 11 that started in 2011, is one of 26 in phase 4, and was the 27th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

None of the 91 studies testing ranibizumab in Macular Edema is open now. The open studies under Macular Edema, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 91 studies testing ranibizumab in Macular Edema as a file.
02

Study summary

This was a Phase IV multicenter, randomized, open-label study, with masking of the vision examiner, of the efficacy and safety of intravitreal ranibizumab 0.5 mg in subjects with macular edema following Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO).

Read the detailed description

This study consisted of 2 study periods, a 7-month fixed treatment period, followed by an 8-month alternate dose regimen period. Subjects could receive up to a maximum of 15 monthly injections of ranibizumab 0.5 mg during the study, 7 injections (Day 0 and at 6 monthly visits) in the fixed treatment period and a maximum of 8 injections in the alternate dose regimen period. During the fixed treatment period, subjects received 7 monthly intravitreal ranibizumab 0.5 mg injections. During the alternate dose regimen period, from Month 7 through Month 14, subjects were evaluated monthly to determine whether they achieved the study-specific visual acuity and spectral-domain optical coherence tomography (VA-OCT) stability criteria. Subjects continued to receive monthly ranibizumab 0.5 mg monthly injections until the VA-OCT stability criteria were first met. Upon meeting the VA-OCT stability criteria for the first time during the alternate dose regimen period, subjects were randomly assigned in a 1:1 ratio to one of 2 dose regimens, the PRN (pro re nata, "as-needed") or the Monthly regimen.

PRN randomized subjects: Subjects received no injection at the randomization visit and at future monthly visits where the VA-OCT stability criteria were met and received a ranibizumab 0.5 mg injection at future monthly visits if the VA-OCT stability criteria were not met.

Monthly randomized subjects: Subjects continued to receive ranibizumab 0.5 mg injections at each monthly visit.

Monthly non-randomized subjects: Subjects who did not meet the VA-OCT stability criteria at any month from Month 7 through Month 14 were not randomized and received 8 monthly intravitreal ranibizumab 0.5 mg injections.

03

Conditions studied

  • Macular Edema

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For sexually active women of , use of an appropriate form of (or abstinence) for the duration of the study.

Ocular Inclusion Criteria (Study Eye)

  • Foveal center-involved macular edema secondary to branch retinal vein occlusion (BRVO) (including hemi-retinal retinal vein occlusion [HRVO]) or central retinal vein occlusion (CRVO).
  • Best corrected visual acuity (BCVA) using Early Treatment Diabetic Retinopathy Study (ETDRS) charts of 20/40 to 20/320 (Snellen equivalent) in the study eye.
  • Mean central subfield thickness > 300 µm on 2 spectral-domain optical coherence tomography measurements (screening and Day 0 [first day of treatment]).

Exclusion criteria

Exclusion Criteria:

  • History of cerebral vascular accident or myocardial infarction within 3 months prior to Day 0.
  • History of any systemic anti-vascular endothelial growth factor (VEGF) or pro-VEGF treatment within 6 months prior to Day 0.
  • History of allergy to fluorescein.
  • History of allergy to ranibizumab injection or related molecule.
  • Relevant systemic disease that may be associated with increased systemic VEGF levels. History of successfully treated is not an exclusion criterion.
  • Uncontrolled blood pressure.
  • Pregnancy or lactation.
  • Daily use of oral to treat a chronic condition.
  • Required treatment with injectable corticosteroids to treat a musculoskeletal condition.
  • Participation in an trial within 30 days prior to Day 0 that involved treatment with any drug or device that has not received regulatory approval at the time of study entry.

Ocular Exclusion Criteria (Study Eye)

  • Prior episode of retinal vein occlusion (RVO).
  • Brisk afferent pupillary defect.
  • History of any previous intravitreal anti-VEGF therapy for RVO in the study eye.
  • History of previous therapeutic treatment for RVO, other than anti-VEGF therapy, within 4 months prior to the screening visit, including any intraocular corticosteroids.
  • History of previous surgical treatment for RVO, including radial optic neurotomy or sheathotomy.
  • History or presence of age-related macular degeneration (AMD) (dry form graded as Age-Related Eye Disease Study [AREDS] Stage 2 or higher or wet form).
  • History of laser photocoagulation for macular edema within 4 months prior to Day 0.
  • History of panretinal scatter photocoagulation or sector laser photocoagulation within 4 months prior to Day 0 or anticipated within the next 4 months following Day 0.
  • History of pars plana vitrectomy.
  • History of intraocular surgery within 2 months prior to Day 0 or anticipated within the next 7 months following Day 0.
  • History of yttrium-aluminum-garnet (YAG) capsulotomy performed within 2 months prior to Day 0.
  • Previous filtration surgery in the study eye.
  • History of herpetic ocular infection.
  • History of ocular toxoplasmosis.
  • History of rhegmatogenous retinal detachment.
  • History of idiopathic central serous chorioretinopathy.
  • Evidence upon examination of vitreoretinal interface disease either on clinical examination or spectral-domain optical coherence tomography (SD-OCT), thought to be contributing to macular edema.
  • Presence of an ocular condition that, in the opinion of the investigator, might affect macular edema or alter visual acuity during the study.
  • Visually significant hemorrhage obscuring the fovea and felt to be a major contributor to reduced visual acuity. The subject should be followed and when the hemorrhage in the fovea clears to the point that it is no longer a major contributor to reduced visual acuity, the subject may be screened for the study.
  • Presence of a substantial cataract that, in the opinion of the investigator, is likely to be decreasing visual acuity by 3 lines or more.
  • Intra-ocular pressure (IOP) ≥ 30 mmHg. If a subject's IOP is ≥ 30 mmHg, that subject will be referred for glaucoma treatment and may be re-screened after 1 month.
  • Evidence upon examination of pseudoexfoliation.
  • Aphakia.
  • Evidence upon examination of external ocular infection, including conjunctivitis, chalazion, or significant blepharitis.
  • Evidence upon examination of any diabetic retinopathy, defined as eyes of diabetic patients with more than one microaneurysm outside the area of the vein occlusion (inclusive of both eyes).
  • Other relevant ocular disease that may be associated with increased intraocular VEGF levels.
  • Improvement of ≥ 10 letters on best-corrected visual acuity ETDRS score between screening and Day 0.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
202 participants (actual)

Study arms

  • Experimental
    Ranibizumab 0.5 mg monthly - randomized subjects

    Subjects received at least 7 monthly intravitreal ranibizumab 0.5 mg injections until the first month where the study-specific visual acuity and spectral-domain optical coherence tomography (VA-OCT) stability criteria were met and randomization occurred to the monthly arm. At subsequent monthly visits after randomization, injections were given whether the VA-OCT stability criteria were met or not met. Subjects were to receive 15 ranibizumab 0.5 mg injections.

    Drug: Ranibizumab

  • Experimental
    Ranibizumab 0.5 mg PRN - randomized subjects

    Subjects received at least 7 monthly intravitreal ranibizumab 0.5 mg injections until the first month where the study-specific VA-OCT stability criteria were met and randomization occurred to the PRN arm. No injection was given at the randomization visit. At subsequent monthly visits after randomization, injections were given if the VA-OCT stability criteria were not met and no injections were given if the VA-OCT stability criteria were met. Subjects could receive between 7 and a maximum of 14 ranibizumab 0.5 mg injections.

    Drug: Ranibizumab

  • Experimental
    Ranibizumab 0.5 mg monthly - non-randomized subjects

    Subjects received at least 7 monthly intravitreal ranibizumab 0.5 mg injections and then never met the study-specific VA-OCT stability criteria from month 7 to month 14. Subjects were to receive 15 ranibizumab 0.5 mg injections.

    Drug: Ranibizumab

Interventions

  • Liquid ranibizumab (10 mg/ml) was supplied in a sterile solution in single-use vials.

    Also known as: Lucentis

06

What researchers measure

Primary outcomes

  1. Trend of Change From Baseline in the Best Corrected Visual Acuity (BCVA) Scores From Month 7 to Month 15

    BCVA was measured in the study eye using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision. A positive change score indicates improvement. The reported data are the observed changes from Baseline in BCVA at Months 7 and 15. For the statistical analysis, the interaction term of treatment by time in a longitudinal model was used to assess whether there was a difference in the trend of change from Baseline in the visual acuity scores from Month 7 to Month 15 between the 2 randomized treatment groups, Monthly and PRN.

    Time frame: Baseline to Month 15

Secondary outcomes

  1. Visual Acuity Change From Previous Month During the Alternate Dose Regimen Period in Subjects Who Met the VA-OCT Stability Criteria at the Previous Month

    BCVA was measured in the study eye using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision. A positive change score indicates improvement. This outcome measure is not relevant for subjects in the non-randomized group because they never met the VA-OCT stability criteria.

    Time frame: Month 7 through Month 15

  2. Percentage of Participants Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline

    BCVA was measured in the study eye using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision.

    Time frame: Month 7 to Month 15

  3. Percentage of Participants With a Visual Acuity (VA) Snellen Equivalent of 20/40 or Better

    VA was measured in the study eye using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart starting at a test distance of 4 meters. An increase in the number of lines read correctly by the patient in the ETDRS chart indicates an improvement of vision. The Snellen equivalent of 20/40 or better is 69 or more letters correctly read in the EDTRS chart.

    Time frame: Month 7 to Month 15

  4. Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score

    BCVA was measured in the study eye using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision. A positive change score indicates improvement.

    Time frame: Month 1 to Month 15

  5. Percentage of Participants Who Lost < 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline

    BCVA was measured in the study eye using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision.

    Time frame: Month 7 to Month 15

  6. Percentage of Participants With a Central Foveal Thickness of ≤ 300 µm

    Central foveal thickness was assessed monthly in the study eye using spectral-domain optical coherence tomography. Central foveal thickness was computed using the automated Cirrus Review software (DOCTR CZM Cirrus OCT Grader Reading Manual, Version 1.02). All participants in the Monthly and PRN groups had a baseline central foveal thickness \> 300 µm at baseline.

    Time frame: Month 7 to Month 15

  7. Mean Change From Baseline in Central Foveal Thickness

    Central foveal thickness was assessed monthly in the study eye using spectral-domain optical coherence tomography. Central foveal thickness was computed using the automated Cirrus Review software (DOCTR CZM Cirrus OCT Grader Reading Manual, Version 1.02). All participants in the Monthly and PRN groups had a baseline central foveal thickness \> 300 µm at baseline. A decrease in foveal thickness suggests a reduction in macular edema. A negative change score indicates improvement.

    Time frame: Month 1 to Month 15

  8. Percentage of Participants With Intraretinal Edema

    The presence of intraretinal edema was defined as the presence of subretinal fluid, cystoid spaces, or central retinal thickness ≥ 300 µm as evaluated in spectral-domain optical coherence tomography images by the Digital Angiography Reading Center, the central reading center. At baseline, all participants in the Monthly and PRN groups had presence of edema.

    Time frame: Month 7 to Month 15

07

Results

Posted Apr 23, 2014

Participant flow

7-Month Fixed Treatment Period
Participant flow — 7-Month Fixed Treatment Period
MilestoneRanibizumab 0.5 mg Monthly - Randomized SubjectsRanibizumab 0.5 mg PRN - Randomized SubjectsRanibizumab 0.5 mg Monthly - Non-randomized Subjects
Started858631
Completed858619
Not completed0012
Withdrew: Subject decision to withdraw008
Withdrew: Lost to follow-up002
Withdrew: Subject required other drug therapy001
Withdrew: Subject non-compliance001
8-Month Alternate Dose Regimen Period
Participant flow — 8-Month Alternate Dose Regimen Period
MilestoneRanibizumab 0.5 mg Monthly - Randomized SubjectsRanibizumab 0.5 mg PRN - Randomized SubjectsRanibizumab 0.5 mg Monthly - Non-randomized Subjects
Started858619
Completed808213
Not completed546
Withdrew: Death010
Withdrew: Lost to follow-up113
Withdrew: Subject decision to withdraw301
Withdrew: Subject non-compliance021
Withdrew: Relocation101

Outcome measures

PrimaryTrend of Change From Baseline in the Best Corrected Visual Acuity (BCVA) Scores From Month 7 to Month 15

BCVA was measured in the study eye using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision. A positive change score indicates improvement. The reported data are the observed changes from Baseline in BCVA at Months 7 and 15. For the statistical analysis, the interaction term of treatment by time in a longitudinal model was used to assess whether there was a difference in the trend of change from Baseline in the visual acuity scores from Month 7 to Month 15 between the 2 randomized treatment groups, Monthly and PRN.

Time frame:
Baseline to Month 15
Reported as:
Mean · Letters
Trend of Change From Baseline in the Best Corrected Visual Acuity (BCVA) Scores From Month 7 to Month 15
LettersRanibizumab 0.5 mg Monthly - Randomized SubjectsRanibizumab 0.5 mg PRN - Randomized Subjects
Month 7 (n=85, 86)17.5 ± 12.619.7 ± 12.6
Month 15 (n=80, 82)18.7 ± 14.121.0 ± 14.1
Statistical analysis
  • Ranibizumab 0.5 mg Monthly - Randomized Subjects vs Ranibizumab 0.5 mg PRN - Randomized Subjects · Longitudinal mixed model · p = 0.5091 (This is the p-value of the treatment by time interaction in the longitudinal model. Analysis was not adjusted for multiple comparisons as there was only 1 comparison. p \< 0.05 (2-sided) was required for significance.) · Estimated interaction effect: 0.071The analysis was stratified by disease (BRVO or CRVO), randomization month, and randomization BCVA score category (≤35, \>35 to ≤50, or \>50 letters).
SecondaryVisual Acuity Change From Previous Month During the Alternate Dose Regimen Period in Subjects Who Met the VA-OCT Stability Criteria at the Previous Month

BCVA was measured in the study eye using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision. A positive change score indicates improvement. This outcome measure is not relevant for subjects in the non-randomized group because they never met the VA-OCT stability criteria.

Time frame:
Month 7 through Month 15
Reported as:
Mean · Letters
Visual Acuity Change From Previous Month During the Alternate Dose Regimen Period in Subjects Who Met the VA-OCT Stability Criteria at the Previous Month
LettersRanibizumab 0.5 mg Monthly - Randomized SubjectsRanibizumab 0.5 mg PRN - Randomized Subjects
Month 8 (n=53, 53)0.4 ± 3.2-3.3 ± 11.3
Month 9 (n=49, 40)0.5 ± 4.0-2.9 ± 8.6
Month 10 (n=52, 31)0.2 ± 3.4-0.5 ± 4.2
Month 11 (n=54, 40)-0.6 ± 3.70.4 ± 4.4
Month 12 (n=46, 44)-0.2 ± 3.2-1.6 ± 4.4
Month 13 (n=50, 41)0.0 ± 3.5-0.5 ± 5.2
Month 14 (n=58, 48)-0.1 ± 3.6-2.2 ± 6.1
Month 15 (n=56, 42)0.0 ± 4.4-0.4 ± 4.0
SecondaryPercentage of Participants Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline

BCVA was measured in the study eye using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision.

Time frame:
Month 7 to Month 15
Reported as:
Number · Percentage of participants
Percentage of Participants Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline
Percentage of participantsRanibizumab 0.5 mg Monthly - Randomized SubjectsRanibizumab 0.5 mg PRN - Randomized SubjectsRanibizumab 0.5 mg Monthly - Non-randomized Subjects
Month 7 (n=85, 86, 17)62.4 (52.1 to 72.7)67.4 (57.5 to 77.3)41.2 (17.8 to 64.6)
Month 15 (n=80, 82, 13)66.3 (55.9 to 76.6)70.7 (60.9 to 80.6)46.2 (19.1 to 73.3)
SecondaryPercentage of Participants With a Visual Acuity (VA) Snellen Equivalent of 20/40 or Better

VA was measured in the study eye using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart starting at a test distance of 4 meters. An increase in the number of lines read correctly by the patient in the ETDRS chart indicates an improvement of vision. The Snellen equivalent of 20/40 or better is 69 or more letters correctly read in the EDTRS chart.

Time frame:
Month 7 to Month 15
Reported as:
Number · Percentage of participants
Percentage of Participants With a Visual Acuity (VA) Snellen Equivalent of 20/40 or Better
Percentage of participantsRanibizumab 0.5 mg Monthly - Randomized SubjectsRanibizumab 0.5 mg PRN - Randomized SubjectsRanibizumab 0.5 mg Monthly - Non-randomized Subjects
Month 7 (n=85, 86, 17)72.9 (63.5 to 82.4)76.7 (67.8 to 85.7)47.1 (23.3 to 70.8)
Month 15 (n=80, 82, 13)71.3 (61.3 to 81.2)76.8 (67.7 to 86.0)46.2 (19.1 to 73.3)
SecondaryMean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score

BCVA was measured in the study eye using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision. A positive change score indicates improvement.

Time frame:
Month 1 to Month 15
Reported as:
Mean · Letters
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score
LettersRanibizumab 0.5 mg Monthly - Randomized SubjectsRanibizumab 0.5 mg PRN - Randomized SubjectsRanibizumab 0.5 mg Monthly - Non-randomized Subjects
Month 1 (n=85, 86, 29)12.2 ± 10.311.2 ± 10.410.7 ± 14.0
Month 7 (n=85, 86, 17)17.5 ± 12.619.7 ± 12.614.7 ± 12.0
Month 15 (n=80, 82, 13)18.7 ± 14.121.0 ± 14.114.5 ± 14.7
SecondaryPercentage of Participants Who Lost < 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline

BCVA was measured in the study eye using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision.

Time frame:
Month 7 to Month 15
Reported as:
Number · Percentage of participants
Percentage of Participants Who Lost < 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline
Percentage of participantsRanibizumab 0.5 mg Monthly - Randomized SubjectsRanibizumab 0.5 mg PRN - Randomized SubjectsRanibizumab 0.5 mg Monthly - Non-randomized Subjects
Month 7 (n=85, 86, 17)98.8 (96.5 to 100.0)98.8 (96.6 to 100.0)100.0 (NA to NA)
Month 15 (n=80, 82, 13)98.8 (96.3 to 100.0)98.8 (96.4 to 100.0)100.0 (NA to NA)
SecondaryPercentage of Participants With a Central Foveal Thickness of ≤ 300 µm

Central foveal thickness was assessed monthly in the study eye using spectral-domain optical coherence tomography. Central foveal thickness was computed using the automated Cirrus Review software (DOCTR CZM Cirrus OCT Grader Reading Manual, Version 1.02). All participants in the Monthly and PRN groups had a baseline central foveal thickness \> 300 µm at baseline.

Time frame:
Month 7 to Month 15
Reported as:
Number · Percentage of participants
Percentage of Participants With a Central Foveal Thickness of ≤ 300 µm
Percentage of participantsRanibizumab 0.5 mg Monthly - Randomized SubjectsRanibizumab 0.5 mg PRN - Randomized SubjectsRanibizumab 0.5 mg Monthly - Non-randomized Subjects
Month 7 (n=85, 86, 17)88.2 (81.4 to 95.1)94.2 (89.2 to 99.1)52.9 (29.2 to 76.7)
Month 15 (n=80, 82, 13)92.5 (86.7 to 98.3)85.4 (77.7 to 93.0)38.5 (12.0 to 64.9)
SecondaryMean Change From Baseline in Central Foveal Thickness

Central foveal thickness was assessed monthly in the study eye using spectral-domain optical coherence tomography. Central foveal thickness was computed using the automated Cirrus Review software (DOCTR CZM Cirrus OCT Grader Reading Manual, Version 1.02). All participants in the Monthly and PRN groups had a baseline central foveal thickness \> 300 µm at baseline. A decrease in foveal thickness suggests a reduction in macular edema. A negative change score indicates improvement.

Time frame:
Month 1 to Month 15
Reported as:
Mean · µm
Mean Change From Baseline in Central Foveal Thickness
µmRanibizumab 0.5 mg Monthly - Randomized SubjectsRanibizumab 0.5 mg PRN - Randomized SubjectsRanibizumab 0.5 mg Monthly - Non-randomized Subjects
Month 1 (n=85, 86, 29)-243.0 ± 172.5-214.9 ± 166.7-157.9 ± 181.8
Month 7 (n=85, 86, 17)-279.7 ± 167.4-265.2 ± 185.9-113.9 ± 184.9
Month 15 (n=80, 82, 13)-289.9 ± 177.2-247.8 ± 207.5-93.2 ± 225.2
SecondaryPercentage of Participants With Intraretinal Edema

The presence of intraretinal edema was defined as the presence of subretinal fluid, cystoid spaces, or central retinal thickness ≥ 300 µm as evaluated in spectral-domain optical coherence tomography images by the Digital Angiography Reading Center, the central reading center. At baseline, all participants in the Monthly and PRN groups had presence of edema.

Time frame:
Month 7 to Month 15
Reported as:
Number · Percentage of participants
Percentage of Participants With Intraretinal Edema
Percentage of participantsRanibizumab 0.5 mg Monthly - Randomized SubjectsRanibizumab 0.5 mg PRN - Randomized SubjectsRanibizumab 0.5 mg Monthly - Non-randomized Subjects
Month 7 (n=85, 86, 17)31.8 (21.9 to 41.7)30.2 (20.5 to 39.9)100.0 (NA to NA)
Month 15 (n=80, 82, 13)25.0 (15.5 to 34.5)32.9 (22.8 to 43.1)84.6 (65.0 to 100.0)

Adverse events

Collected over Adverse Events were reported beginning at initiation of study treatment up to 30 days following the last administration of study treatment, study discontinuation, or termination, whichever was earlier.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ranibizumab 0.5 mg Monthly - Randomized Subjects—12/85 (14.1%)70/85 (82.4%)
Ranibizumab 0.5 mg PRN - Randomized Subjects—14/86 (16.3%)61/86 (70.9%)
Ranibizumab 0.5 mg Monthly - Non-randomized Subjects—11/31 (35.5%)18/31 (58.1%)
Most frequent serious events
Showing 10 of 45
Most frequent serious events
EventRanibizumab 0.5 mg Monthly - Randomized SubjectsRanibizumab 0.5 mg PRN - Randomized SubjectsRanibizumab 0.5 mg Monthly - Non-randomized Subjects
Visual acuity reducedEye disorders1/853/860/31
Coronary artery diseaseCardiac disorders0/850/861/31
DeathGeneral disorders0/850/861/31
DiverticulitisInfections and infestations0/850/861/31
Neck injuryInjury, poisoning and procedural complications0/850/861/31
Back painMusculoskeletal and connective tissue disorders0/850/861/31
Pain in extremityMusculoskeletal and connective tissue disorders0/850/861/31
Pathological fractureMusculoskeletal and connective tissue disorders0/850/861/31
Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/850/861/31
Lung cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/850/861/31
Most frequent other events
Showing 10 of 37
Most frequent other events
EventRanibizumab 0.5 mg Monthly - Randomized SubjectsRanibizumab 0.5 mg PRN - Randomized SubjectsRanibizumab 0.5 mg Monthly - Non-randomized Subjects
Conjunctival haemorrhageEye disorders28/8523/869/31
Eye painEye disorders8/8514/864/31
HypertensionVascular disorders13/858/862/31
Retinal exudatesEye disorders13/8512/863/31
Vitreous detachmentEye disorders11/856/863/31
NasopharyngitisInfections and infestations10/857/861/31
CataractEye disorders9/856/860/31
Macular fibrosisEye disorders9/855/862/31
Upper respiratory tract infectionInfections and infestations3/853/863/31
Vitreous adhesionsEye disorders0/850/863/31

Baseline characteristics

Intent-to-treat population: All enrolled participants who received at least 1 ranibizumab injection in the study.

Age, Continuous
Age, Continuous(years)Ranibizumab 0.5 mg Monthly - Randomized SubjectsRanibizumab 0.5 mg PRN - Randomized SubjectsRanibizumab 0.5 mg Monthly - Non-randomized SubjectsTotal
Mean67.3 ± 12.165.2 ± 12.866.3 ± 12.366.3 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)Ranibizumab 0.5 mg Monthly - Randomized SubjectsRanibizumab 0.5 mg PRN - Randomized SubjectsRanibizumab 0.5 mg Monthly - Non-randomized SubjectsTotal
Female3837984
Male474922118
08

Study locations

42 sites
  • Phoenix, Arizona 85020, United States
  • Tucson, Arizona 85704, United States
  • Beverly Hills, California 90211, United States
  • Chico, California 95973, United States
  • Mountain View, California 94040, United States
  • Oakland, California 94609, United States
  • San Francisco, California 94107, United States
  • Santa Ana, California 92705, United States
  • Santa Barbara, California 93103, United States
  • Torrance, California 90503, United States
  • Colorado Springs, Colorado 80909, United States
  • Golden, Colorado 80401, United States
  • New London, Connecticut 06320, United States
  • Altamonte Springs, Florida 32701, United States
  • Boynton Beach, Florida 33426, United States
  • Lakeland, Florida 33805, United States
  • Augusta, Georgia 30909, United States
  • Chicago, Illinois 60637, United States
  • Baltimore, Maryland 21287, United States
  • Hagerstown, Maryland 21740, United States
  • Boston, Massachusetts 02114, United States
  • Worcester, Massachusetts 01605, United States
  • Jackson, Michigan 49201, United States
  • Edina, Minnesota 55435, United States
  • Las Vegas, Nevada 89144, United States
  • Northfield, New Jersey 08225, United States
  • Teaneck, New Jersey 07666, United States
  • Rochester, New York 14620, United States
  • Charlotte, North Carolina 28210, United States
  • Camp Hill, Pennsylvania 17011, United States
  • Philadelphia, Pennsylvania 19107, United States
  • Pittsburgh, Pennsylvania 15212, United States
  • Pittsburgh, Pennsylvania 15213, United States
  • Ladson, South Carolina 29456, United States
  • West Columbia, South Carolina 29169, United States
  • Rapid City, South Dakota 57701, United States
  • Nashville, Tennessee 37203, United States
  • Abilene, Texas 79606, United States
  • Austin, Texas 78705, United States
  • Houston, Texas 77030, United States
  • San Antonio, Texas 78240, United States
  • The Woodlands, Texas 77384, United States
09

References and documents

Publications

  • Lloyd Clark W, Liu M, Kitchens J, Wang PW, Haskova Z. Baseline characteristics associated with early visual acuity gains after ranibizumab treatment for retinal vein occlusion. BMC Ophthalmol. 2019 Jan 8;19(1):11. doi: 10.1186/s12886-018-1012-y. PubMed 30621653 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2011
First posted
Jan 14, 2011
Start
Feb 2011
Primary completionActual
Oct 2012
CompletionActual
Oct 2012
Results first posted
Apr 23, 2014
Last update
Apr 23, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01277302
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Jan 14, 2011
Start date
Feb 2011
Primary completion
Oct 2012
Completion
Oct 2012
Results posted
Apr 23, 2014
Last update
Apr 23, 2014

Study contacts

Gary Sternberg, M.D.
study director · Genentech, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion